Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2019 Apr 5;12(4):e227516.
doi: 10.1136/bcr-2018-227516.

Very low carbohydrate diet and SGLT-2-inhibitor: double jeopardy in relation to ketoacidosis

Ninna Hahn Tougaard  1 , Jens Faber  1   2 , Ebbe Eldrup  1
Affiliations
Case Reports

Very low carbohydrate diet and SGLT-2-inhibitor: double jeopardy in relation to ketoacidosis

Ninna Hahn Tougaard et al. BMJ Case Rep. .

Abstract

Diabetic euglycaemic ketoacidosis is a possible adverse effect of sodium-glucose co-transporter-2 inhibitors (SGLT2i). We report a case in which the combination of SGLT2i and a strict very low-carbohydrate diet led to severe diabetic ketoacidosis in a young Caucasian man with type 2 diabetes.

Keywords: diabetes; diet; drugs: endocrine system; endocrine system; unwanted effects/adverse reaction.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

References

    1. Kasichayanula S, Liu X, Lacreta F, et al. . Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2. Clin Pharmacokinet 2014;53:17–27. 10.1007/s40262-013-0104-3 - DOI - PubMed
    1. Steen O, Goldenberg RM. The Role of Sodium-Glucose Cotransporter 2 Inhibitors in the Management of Type 2 Diabetes. Can J Diabetes 2017;41:517–23. 10.1016/j.jcjd.2017.08.241 - DOI - PubMed
    1. Rosenstock J, Ferrannini E. Euglycemic Diabetic Ketoacidosis: A Predictable, Detectable, and Preventable Safety Concern With SGLT2 Inhibitors. Diabetes Care 2015;38:1638–42. 10.2337/dc15-1380 - DOI - PubMed
    1. European Medicines Agency. Review of diabetes medicines called SGLT2 inhibitors started. https://www.ema.europa.eu/en/documents/referral/sglt2-inhibitors-article... (Accessed 1Mar 2018).
    1. Yabe D, Iwasaki M, Kuwata H, et al. . Sodium-glucose co-transporter-2 inhibitor use and dietary carbohydrate intake in Japanese individuals with type 2 diabetes: A randomized, open-label, 3-arm parallel comparative, exploratory study. Diabetes Obes Metab 2017;19:739–43. 10.1111/dom.12848 - DOI - PMC - PubMed

Publication types

MeSH terms

Substances